Phase 4
Completed N=118
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
Source: ClinicalTrials.gov NCT01161563 ↗Enrolled (actual)
118
Serious AEs
0.0%
Results posted
Sep 2013
Primary outcomePrimary: Patient Bother From Injection Site Burning and/or Stinging — 23.87; 5.84 units on a scale
Summary
The purpose of this study is to compare how subjects feel after receiving injections of two different types of GnRH six months apart. One injection is given under the skin of the abdomen, and the other one into the muscle of the buttock or thigh.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patient Bother From Injection Site Burning and/or Stinging |
23.87; 5.84 | — |
| SECONDARY Discomfort From Injection |
20.53; 5.88 | — |
Eligibility Criteria
Inclusion Criteria
- Male patients with a diagnosis of advanced prostate cancer for whom treatment with triptorelin pamoate or leuprolide acetate is indicated;
- At least 18 years of age;
- Life expectancy of at least 1 year;
- Capable of completing the study questionnaires without assistance.
Exclusion Criteria
- Patients for whom treatment with triptorelin pamoate or leuprolide acetate is contraindicated;
- Known hypersensitivity to triptorelin, leuprolide or any other GnRH or luteinizing hormone releasing hormone (LHRH) agonists, or GnRH or LHRH;
- Clinically significant systemic disease or condition that would, in the investigator's opinion, lead to undue risk following administration of either triptorelin or leuprolide;
- History of alcohol/drug abuse within the past year;
- History of significant medical problems that may confound the outcome of this study;
- Requires concomitant medications that may affect study assessments (e.g., topical medications used for pretreatment of injection site pain);
- Participated in another investigational drug study within 30 days
- Judged by the investigator to be unsuitable for enrollment in this study for any reason
Data sourced from ClinicalTrials.gov (NCT01161563). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.